Sea-urchin-like bimetallic nickel–cobalt phosphide/phosphate was found to show superior charge storage performance as a battery material for hybrid supercapacitors.

Genistein (4',5,7-trihydroxyisoflavone), a naturally occurring phenolic compound, possesses well-known preventive activity in breast and prostate cancer, cardiovascular diseases, and postmenopausal problems. The aim of this study is to investigate the distribution and dose-dependent absorption, metabolism, and excretion of genistein in rats. Genistein was orally administered to rats at different doses. At various time intervals, blood, bile, and urine samples were collected and incubated with glucuronidase to hydrolyze the glucuronidated genistein. Genistein was detected by HPLC. High levels of glucuronidated genistein were detected in the plasma, bile, and urine after genistein administration. When genistein was administered to rats at 6.25, 12.5, and 50 mg x kg (-1) doses, the AUC (0- t) values for genistein were 23.5, 80.9, and 177.9 mg x min x L (-1); the oral absolute bioavailabilities were 21.9, 33.5, and 19.0%; the AUC (0- t) values of glucuronidated genistein were 173.8, 470.7, and 1721.2 mg x min x L (-1), respectively. The cumulative biliary excretion of genistein respective to each dose was 42.6 +/- 6.5, 75.2 +/- 18.9, and 126.6 +/- 34.8 microg; the cumulative biliary excretion of glucuronidated genistein was 108.5 +/- 35.2, 423.5 +/- 158.3, and 853.7 +/- 320.8 microg for each dose, respectively. The cumulative urinary excretion of genistein was 34.8 +/- 10.8, 187.3 +/- 67.0 and 213.6 +/- 30.6 microg for each dose, respectively; the cumulative levels of glucuronidated genistein excreted in the urine were 217.8 +/- 52.1, 583.1 +/- 106.9, and 1108.4 +/- 88.1 microg, respectively. These results indicated that at high doses absorption, biotransformation, and excretion of genistein occurred in a nonlinear dose-dependent manner. Therefore, the results of these pharmacokinetic studies raise important questions about the therapeutic significance of consuming large quantities of genistein, genistein analogues, or soy-based neutraceuticals.

No abstract

Solid-state lithium-metal batteries attract great attention due to their high energy density and superior safety. However, the sluggish Li + kinetics of solid electrolyte and poor interface compatibility between electrolyte and lithium anode lead to unsatisfied performance at room temperature, which severely limit their practical application. Herein, a Janus quasi-solid electrolyte (JSE) design is reported, which modifies the Li + solvation environment in succinonitrile (SN) plastic crystal electrolyte and creates 1D Li + transportation channels. Density functional theory calculations and Raman results reveal that Li 1.3 Al 0.3 Ti 1.7 (PO 4 ) 3 changes the Li + solvation environment from SN units to aggregated ion pairs, which accelerates the diffusion rate of Li + . As a result, JSE presents excellent ionic conductivity (0.73 mS cm −1 ) and high lithium transference number (0.72). With this efficient JSE, Li symmetric cells deliver excellent cycle stability over 600 h with a low over potential of 60 mV. LiFePO 4 |JSE|Li solid-state battery delivers an impressive performance with a specific discharge capacity of 152 mAh g −1 after 100 cycles at room temperature under 0.5 C. Moreover, the corresponding pouch cell also shows outstanding performance (140 mAh g −1 under 0.5 C) and withstands abuse tests such as bending and cutting, demonstrating its superior safety for future utilization.